Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

is announcement.

Part IINot for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.RECOMMENDED COMBINATION OF SHIRE PLC AND ABBVIE INC.1.
IntroductionThe Boards of Shire and AbbVie are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

2.
The MergerUnder the terms of the Merger, Shire Shareholders will be entitled to receive:
in respect of each Shire Share: £24.44 in cash and 0.8960 New AbbVie Shares

  • The Merger terms represent:
  • An indicative value of £52.48 per Shire Share based on AbbVie's closing share price of $53.52 on 17 July 2014, the Latest Practicable Date; and
  • An indicative value of £53.19 per Shire Share based on AbbVie's 30-day Volume-Weighted Average Price of $54.83 to 17 July 2014, the Latest Practicable Date.
  • The indicative value of £53.19 per Shire Share values the entire issued and to be issued share capital of Shire on a fully diluted basis at approximately £32 billion and represents:
  • A premium of approximately 53 per cent. to the price of Shire Shares of £34.67 on 2 May 2014, being the last Business Day prior to AbbVie's initial proposal;
  • A premium of approximately 42 per cent. to the price of Shire Shares of £37.38 on 19 June 2014, being the last Business Day prior to the commencement of the offer period; and
  • An implied Enterprise Value / Last Twelve Months EBITDA multiple of approximately 24x.
  • On the basis of approximately 536 million New AbbVie Shares being issued pursuant to the Merger, following the Transaction, Shire Shareholders will hold New AbbVie Shares representing approximately 25 per cent. of the issued share capital of New AbbVie and AbbVie Stockholders will hold New AbbVi
    '/>"/>

  • SOURCE AbbVie Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
    2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
    3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
    4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
    5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
    6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
    7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
    8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
    10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
    11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
    (Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
    (Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
    ... NEW YORK, Nov. 3, 2011 Intellect Neurosciences, ... the discovery and development of disease-modifying therapeutic agents ... diseases announced today that it has filed a ... its antibody methods application Serial  No. 10/084,380, one ...
    ... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... ended September 30, 2011, which reflect the Company,s continuing investment ... quarter with $202.7 million in cash and short-term investments, a ... quarter of 2011, the Company had a net loss of ...
    Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
    (Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
    (Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
    (Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
    Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
    ... reveals that there is no association between a restaurant worker,s ... able to provide a safe meal to a food allergic customer. ... as 8% of children in the UK alone. Allergic reactions can ... which can cause death. Led by Professor Helen Smith of Brighton ...
    ... care improves medical outcomes, investigators from the Regenstrief ... providing a call to action for the training ... well as the burgeoning scientific knowledge needed to ... the Patient-Centered Divide: Transforming Health Care Quality Through ...
    ... the National Institute of Standards and Technology (NIST) ... disease, an inherited degenerative brain disorder that usually ... leads to physical impairment, dementia and death. A ... has a 50-50 chance of getting the currently ...
    ... , This release is available in French ... of Granada research group composed of professors Antonio Campos ... and Juan de la Cruz Cardona (opticians) and the ophthalmologist ... the first bioartificial organ in Spain Researchers extracted pig ...
    ... release is available in French . Montreal, ... treat tics in Tourette syndrome may be as effective as ... a new study published in a special edition of the ... Research Centre of the Louis-H. Lafontaine Hospital affiliated with Universit ...
    ... Toronto General Hospital, University Health Network have shown in ... safely and effectively treat, re-assess and improve the function ... successfully transplanted into patients. The use of this technique ... outcomes after transplantation. In their pioneering work, a ...
    Cached Medicine News:Health News:Training future doctors to enlist patients as partners in care 2Health News:New NIST SRM helps improve diagnosis of Huntington's disease 2Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 3Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 4
    ... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
    ... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
    ... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
    Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
    Medicine Products: